Eliglustat
Gaucher Disease, Type III
National Taiwan University HospitalSmall moleculeN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 95/ 100
Competitive context
7 Active assets in the Gaucher Disease, Type III cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Elelyso Ari Zimran | Phase 4 | BB |
Cerezyme Sanofi | Phase 3 | BB |
Eliglustat Sanofi | Phase 3 | BB |
Venglustat Sanofi | Phase 3 | B |
Velaglucerase Alfa Shire | Phase 1/2 | CCC |
View all 10 →
Same molecule, other indications
Eliglustat is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →